Levisonics

Executive Summary

Levisonics, Inc. is a Cambridge-based medical device startup founded in 2016, spun out of research collaborations between Boston University and Tulane University. The company is developing a novel platform for blood coagulation analysis and fluid rheological measurement. This technology addresses a critical need in point-of-care diagnostics for patients on anticoagulant therapy, hemophilia management, and surgical settings where rapid, accurate clotting assessment is essential. By leveraging acoustic or microfluidic principles (implied by name 'Levisonics'), the platform aims to provide real-time, lab-quality results at the bedside, potentially reducing turnaround times and improving patient outcomes. While still in early stages with no disclosed funding or commercial products, Levisonics operates in a sizable market with established competitors, but its differentiated approach may offer advantages in simplicity and cost. The company's academic pedigree and focus on an unmet clinical need position it as a potential candidate for seed or Series A funding in the near future.

Upcoming Catalysts (preview)

• Q4 2026Completion of proof-of-concept studies and publication of results70% success
• Q2 2027Seed or Series A funding round closing60% success
• Q1 2027Strategic partnership with a diagnostic or pharmaceutical company for co-development40% success